{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:29:32Z","timestamp":1761823772713,"version":"3.40.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","worldneurosurgery.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.wneu.2016.02.070","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T17:49:19Z","timestamp":1457200159000},"page":"262-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Management Overview: Taking a Patient with Intracranial Hemorrhage Related to Direct Oral Anticoagulants to the Operating Room"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4613-5640","authenticated-orcid":false,"given":"Abdulrahman","family":"Alturki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Badawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Teitelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2016.02.070_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jth.12969","article-title":"Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH","volume":"13","author":"Barnes","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.wneu.2016.02.070_bib2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based design of novel potent nonpeptide thrombin inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.wneu.2016.02.070_bib3","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1160\/TH09-02-0134","article-title":"Direct inhibitors of coagulation proteins-the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy","volume":"102","author":"Laux","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.wneu.2016.02.070_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11239-013-0967-z","article-title":"The pharmacology of novel oral anticoagulants","volume":"37","author":"DeWald","year":"2014","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.wneu.2016.02.070_bib5","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1002\/ajh.23202","article-title":"Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors","volume":"87","author":"Kaatz","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.wneu.2016.02.070_bib6","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/blood-2013-09-529784","article-title":"How I treat target-specific oral anticoagulant\u2013associated bleeding","volume":"123","author":"Siegal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2016.02.070_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jth.12096","article-title":"Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants","volume":"11","author":"Garcia","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.wneu.2016.02.070_bib8","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1345\/aph.1R179","article-title":"Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in\u00a0vitro study","volume":"46","author":"Dager","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.wneu.2016.02.070_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.thromres.2011.01.001","article-title":"Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement","volume":"127","author":"Freyburger","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.wneu.2016.02.070_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11239-013-0933-9","article-title":"Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG(\u00ae)) to guide decision-making","volume":"37","author":"Neyens","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.wneu.2016.02.070_bib11","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2016.02.070_bib12","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2016.02.070_bib13","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMp1302834","article-title":"Dabigatran and postmarketing reports of bleeding","volume":"368","author":"Southworth","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2016.02.070_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation","volume":"131","author":"Graham","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.wneu.2016.02.070_bib15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2016.02.070_bib16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2016.02.070_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.acvd.2013.04.009","article-title":"Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)\u2013March 2013","volume":"106","author":"Pernod","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.wneu.2016.02.070_bib18","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.wneu.2016.02.070_bib19","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A\u00a0specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2016.02.070_bib20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2016.02.070_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMe1506600","article-title":"Targeted anti-anticoagulants","volume":"373","author":"Bauer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2016.02.070_bib22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2016.02.070_bib23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A\u00a0specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2016.02.070_bib24","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2016.02.070_bib25","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMe1513258","article-title":"Antidote for Factor Xa Anticoagulants","volume":"373","author":"Connors","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2016.02.070_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"Chang","year":"2013","journal-title":"Am J Kidney Dis"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875016003156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875016003156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T04:00:22Z","timestamp":1567656022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875016003156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":26,"alternative-id":["S1878875016003156"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2016.02.070","relation":{},"ISSN":["1878-8750"],"issn-type":[{"type":"print","value":"1878-8750"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management Overview: Taking a Patient with Intracranial Hemorrhage Related to Direct Oral Anticoagulants to the Operating Room","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2016.02.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}